Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 16, 2023 (Event Date)
Reporting Period: The filing addresses a compliance issue regarding the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
Key Financial Metrics
This filing is a notice of regulatory noncompliance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the receipt of a notice from the New York Stock Exchange (NYSE) stating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual. This noncompliance is due to the failure to timely file the Form 10-Q for the quarter ended September 30, 2023.
Outlook, Risks, and Management Commentary
- Regulatory Status: The Company has contacted the NYSE to discuss the status of its quarterly filing.
- Public Disclosure: A press release regarding the notice of noncompliance was issued on November 24, 2023.
- Risk: Failure to satisfy continued listing rules may lead to delisting proceedings if the filing is not remedied within the timeframe allowed by the exchange.
Investor Verification Checklist
- Verify the current status of the Form 10-Q for the quarter ended September 30, 2023, and whether it has been filed.
- Confirm the Company's standing with the NYSE regarding the Section 802.01E compliance notice.
- Review the press release dated November 24, 2023 (Exhibit 99.1) for additional details on the remediation plan.
- Monitor for any subsequent filings regarding potential delisting or extension requests.